EGFR and neoplasm: Subsequent studies optimized this strategy for in vitro use by combining scFv-VSV-G fusion activity with poloxamer-based adjuvants, achieving the efficient transduction of difficult-to-transduce cells like CD30+ lymphoma cells, CD34+ hematopoietic stem cells, EGFR+ tumor cells, and T cells [92,124].